IMpower150最终探索性分析:ABCP方案在EGFR突变及肝/脑转移NSCLC亚组中的疗效
IMpower150 III期研究最终探索性分析显示,在化疗初治的转移性非鳞NSCLC中,ABCP方案对比BCP在致敏性EGFR突变(HR=0.60,95%CI 0.31-1.14)和基线肝转移(HR=0.68,95%CI 0.45-1.02)亚组中持续显示OS改善,而ACP方案无生存获益;ABCP对延迟新发脑转移的影响需进一步研究。
要点
- ABCP对比BCP在致敏性EGFR突变亚组HR=0.60(95%CI 0.31-1.14),既往TKI亚组HR=0.74(95%CI 0.38-1.46)。
- ABCP对比BCP在基线肝转移亚组HR=0.68(95%CI 0.45-1.02)。
- ACP对比BCP在EGFR突变及肝转移亚组均无生存获益,新发脑转移延迟趋势需进一步验证。
核心结论
- ABCP对比BCP在致敏性EGFR突变(含既往TKI失败)和基线肝转移亚组中显示OS获益,但需谨慎解读。
- ACP对比BCP在致敏性EGFR突变或肝转移亚组中未显示生存获益。
- ABCP对延迟新发脑转移的影响需进一步研究。
研究设计与样本
- III期IMpower150研究(NCT02366143)最终探索性分析,纳入1202例化疗初治的转移性非鳞NSCLC患者(意向治疗人群)。
- 患者随机分配至ABCP、ACP或BCP组,允许纳入经治疗且稳定的脑转移患者。
- 数据截止2019年9月13日,中位随访39.3个月;评估EGFR突变和基线肝转移亚组的OS,以及意向治疗人群新发脑转移的发生率和发生时间。
主要发现
- ABCP对比BCP在致敏性EGFR突变全部患者中HR=0.60(95%CI 0.31-1.14),既往TKI患者中HR=0.74(95%CI 0.38-1.46)。
- ABCP对比BCP在基线肝转移患者中HR=0.68(95%CI 0.45-1.02)。
- ACP对比BCP在致敏性EGFR突变全部患者中HR=1.0(95%CI 0.57-1.74),既往TKI患者中HR=1.22(95%CI 0.68-2.22)。
- ACP对比BCP在肝转移患者中HR=1.01(95%CI 0.68-1.51)。
- 共100例患者(8.3%)发生新发脑转移;ABCP对比BCP显示延迟发生趋势(HR=0.68,95%CI 0.39-1.19),但未正式评估。
临床怎么用
- 对于致敏性EGFR突变(含既往TKI治疗失败)或基线肝转移的转移性非鳞NSCLC患者,ABCP方案可作为考虑选项,但需谨慎解读探索性分析结果。
- ACP方案在EGFR突变或肝转移亚组中未显示优于BCP的生存获益,不作为推荐依据。
- ABCP对延迟新发脑转移的作用尚不明确,需进一步研究验证。
局限性
- 该分析为探索性亚组分析,结果应谨慎解读。
- ABCP对延迟新发脑转移的影响未进行正式评估,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Final overall survival (OS) analyses are presented for EGFR mutations and liver or brain metastases subgroups in the phase 3 IMpower150 study (NCT02366143) evaluating atezolizumab plus bevacizumab plus carboplatin and paclitaxel (ABCP) or atezolizumab plus carboplatin and paclitaxel (ACP) versus bevacizumab plus carboplatin and paclitaxel (BCP). METHODS: Overall, 1202 patients (intention-to-treat population) with chemotherapy-naive, metastatic, nonsquamous NSCLC were randomized to ABCP, ACP, or BCP. Patients with treated, stable brain metastases were permitted. OS was evaluated in EGFR mutations and baseline liver metastases subgroups; rate and time to development of new brain metastases were evaluated in the intention-to-treat patients. RESULTS: At data cutoff (September 13, 2019; median follow-up, 39.3 mo), OS improvements were sustained with ABCP versus BCP in sensitizing EGFR mutations (all: hazard ratio [HR] = 0.60; 95% confidence interval [CI]: 0.31-1.14; previous tyrosine kinase inhibitor [TKI]: HR = 0.74; 95% CI: 0.38-1.46) and baseline liver metastases (HR = 0.68; 95% CI: 0.45-1.02) subgroups. ACP did not have survival benefit versus BCP in sensitizing EGFR mutations (all: HR = 1.0; 95% CI: 0.57-1.74; previous TKI: HR = 1.22; 95% CI: 0.68-2.22) or liver metastases (HR = 1.01; 95% CI: 0.68-1.51) subgroups. Overall, 100 patients (8.3%) developed new brain metastases. Although not formally evaluated, an improvement toward delayed time to development was found with ABCP versus BCP (HR = 0.68; 95% CI: 0.39-1.19). CONCLUSIONS: This final exploratory analysis revealed OS benefits for ABCP versus BCP in patients with sensitizing EGFR mutations, including those with previous TKI failures, and with liver metastases, although these results should be interpreted with caution. The impact of ABCP on delaying the development of new brain lesions requires further investigation.
引用
- Nogami N, Barlesi F, Socinski MA, et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol. 2021. PMID: 34626838. doi:10.1016/j.jtho.2021.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。